
The injection of dexamethasone intraocular suspension 9% into the capsular bag may change the standard of care following cataract surgery.

The injection of dexamethasone intraocular suspension 9% into the capsular bag may change the standard of care following cataract surgery.

Anton Vlasov, DO, moved to the United States in 2001 at the age of 14, but since Russia invaded his homeland last month, the safety of family still living in Ukraine has weighed heavy on his mind.

Physicians find the Vivity lens offers their patients reduced glare, halos and increased spectacle independence.

The key factors include type, case complexity, and history of diabetic retinopathy/proliferative diabetic retinopathy.

Dr. Rishi Raj Borah, Country Director with Orbis India, discusses recent research he co-authored showing the top 3 barriers keeping families from accessing cataract treatment for their children in India.

Lisa M. Nijm, MD, JD, previews the program for this April 2 virtual event designed to help young ophthalmologists learn everything they need to know when starting practice.

Kathryn A. Colby, MD, PhD, discusses Fuchs’ dystrophy symptoms and treatment options as well as the underlying concept of Descemet stripping only surgery and her role in pioneering this technique.

The company this week is rolling out its Clareon family of IOLs, including Monofocal, PanOptix and Vivity options.

Oculoplastic surgeons are experts at ptosis surgery. However, surgery is not for everyone, according to Andrea Kossler, MD.

The company notes that the system’s design includes a small footprint, enhanced ergonomics, superior imaging, dual-pulsed laser, and advanced astigmatism management tools.

The company’s new technology, which targets the eye’s conventional outflow pathway, is expected to have full commercial availability on April 1.

New World Medical notes that the intuitively designed Streamline features ClickPulse technology that targets the eye’s conventional outflow pathway.

The eye care nonprofit has continually harnessed the power of innovation to reach new heights in the fight against avoidable blindness.

This novel surgical system could dramatically improve outcomes for patients with glaucoma with its remarkable level of precision that is unachievable during standard glaucoma surgery.

Study investigators compared 2 novel lens designs using data obtained from 19 investigational sites in Australia, Canada, Spain, and the UK

The company is revealing the 8-year follow up results of its novel Elios Excimer Laser Trabeculostomy procedure combined with cataract surgery.

While there is currently no cure for blindness, an artificial vision system has undergone its first successful implantation, bringing with it the potential to restore partial vision to people who have lost their sight.

Results from the study were presented by Russell Tait, PhD, CEO of PolyActiva, at the Glaucoma 360 New Horizons Forum in San Francisco, California

Utilizing new technology, surgeons can be 20 to 40 times more precise.

Proper measurement of the eye is key to predicting lens strength.

Andrew G. Iwach, MD, co-founder and co-chair of Glaucoma 360, Glaucoma Center of San Francisco, speaks with Ophthalmology Times’® Sheryl Stevenson on his presentation regarding trends and challenges of glaucoma.

Shan C. Lin, MD, explains why ophthalmologists should be mindful of refractive considerations in cataract surgery for their patients with glaucoma.

The introduction of new devices is possibly the single most influential factor currently driving the glaucoma market, said Kristen Harmon Ingenito, MBA, in her presentation during the New Horizons Forum at the 2022 Glaucoma 360.

Ranya Habash, MD, medical director of Technology Innovation, assistant professor of Clinical Ophthalmology at Bascom Palmer Eye Institute, University of Miami in Miami, Florida, offers a preview of her New Horizons keynote speech on "The future of eye care: science fiction to science fact."

Ora Chief Medical Officer Gustavo De Moraes, MD, PhD, MPH, speak with Ophthalmology Times®' Sheryl Stevenson to discuss some of the cutting-edge advancements in therapies and diagnostics for the treatment of glaucoma patients.